Abstract 39P
Background
Prostate cancer (PCa) is one of the leading malignant diseases in men worldwide. The presence of myeloid-derived suppressor cells (PMN-MDSCs) is a critical contributor to a pro-tumorigenic microenvironment in advanced disease, where the neutrophil-lymphocyte ratio (NLR) is prognostic. However, their involvement in the early stages of PCa is still unclear.
Methods
Patients affected by localized prostate cancer and undergoing radical prostatectomy at the Urology Department of the University Hospital of Padua were enrolled in the study after signing informed consent. Blood and tumor samples from 79 patients were collected and immunostained for flow cytometry analysis. Disease risk groups were assigned according to EAU guidelines. Correlation between experimental data and clinical and anatomopathological features was done by logistic regression and Sperman’s correlation.
Results
No association between neutrophil counts and NLR with oncological outcome was found in a population of 79 patients with localized prostate cancer. However, a subset of circulating immature myeloid cells was found to be associated with higher disease risk groups (OR = 1.19 CI.95 (1.02, 1.38), p-value = 0.027). Of note, primary tumor lesions did not reveal a significant enrichment of the immune infiltrate and any association with clinical scores. Further analyses on defining a new potential circulating biomarker showed encouraging results. Gene expression analyses are ongoing.
Conclusions
Localized PCa is not associated with a higher circulating number of neutrophils and higher NLR compared with healthy subjects. However, further analyses of specific myeloid cell subsets are needed.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract